Award of Share Options and Restricted Stock Units
April 23 2018 - 5:45AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), announces that
the following options over new ordinary shares of one penny nominal
value (‘Ordinary Shares’) were granted on 20 April 2018 to the
Chief Executive Officer, PDMRs and employees in line with the
Company’s Long Term Incentive Plan. The Company has also made a
grant of restricted stock units (‘RSUs’) to the Non-Executive
Directors under the Company’s 2017 Remuneration Policy. Details of
both grants are summarised below.
Grant of Share Options
Director/PDMR |
Position |
Type |
Options Awarded |
All Options Capable of Vesting |
Glyn Edwards |
Chief Executive Officer |
Annual |
458,978 |
|
|
|
Retention |
900,000 |
3,465,955 |
Erik Ostrowski |
Chief Financial Officer |
Annual |
160,000 |
|
|
|
Retention |
800,000 |
1,376,557 |
David Roblin |
Chief Operating Officer, President of R&D |
Annual |
160,000 |
791,208 |
The option awards to Glyn Edwards and Erik
Ostrowski comprise two parts: the annual option award, and a second
award of retention share options. All options awarded to Glyn
Edwards, Erik Ostrowski and David Roblin have an exercise price of
205 pence per share and will vest in full on 20 April 2021 subject
to achievement of performance conditions pertaining to corporate
and programme development milestones.
Options over 982,450 Ordinary Shares were
granted to other employees of the Company. These options have an
exercise price of 205 pence per share. They will vest in nine equal
tranches on a quarterly basis from 20 April 2019 and will vest in
full on 20 April 2021. The exercise price was the mid-market
closing price of the ordinary shares on 20 April 2018.
The total number of share options that are
capable of vesting is 10,026,784.
Award of Restricted Stock Units
Director |
Position |
RSU’s Awarded |
Total RSUs Held |
Frank Armstrong |
Non-Executive Chairman |
36,585 |
119,347 |
Barry Price |
Non-Executive Director |
17,073 |
55,696 |
Stephen Davies |
Non-Executive Director |
17,073 |
55,696 |
Leopoldo Zambeletti |
Non-Executive Director |
17,073 |
55,696 |
Valerie Andrews |
Non-Executive Director |
17,073 |
55,696 |
Dave Wurzer |
Non-Executive Director |
17,073 |
55,696 |
Each RSU entitles the holder to subscribe for an
Ordinary Share at a subscription price of one penny per Ordinary
Share. The RSUs have a vesting period of one year and no
performance conditions. The RSUs granted will vest on 20 April
2019.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn
Edwards / Richard Pye (UK office) |
Tel: |
44
(0)1235 443 951 |
Erik
Ostrowski / Michelle Avery (US office) |
|
+1
617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44
(0)20 7213 0880 |
Liam
Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44
(0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
|
|
Panmure Gordon (Joint Broker) |
Tel: |
+44
(0)20 7886 2500 |
Freddy Crossley, Corporate Finance |
|
|
Tom
Salvesen, Corporate Broking |
|
|
|
|
|
MacDougall Biomedical Communications (US) |
Tel: |
+1
781 235 3060 |
Karen
Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44
(0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner / Lindsey Neville |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024